Peer Reviewed





Background: Peripartum cardiomyopathy and doxorubicin-induced cardiomyopathy are well described conditions but there is little description in the literature of both occurring together.

Case: A 29 year old G1P0 with a remote history of childhood chondroblastic osteosarcoma treated with high-dose doxorubicin therapy who developed minimally symptomatic cardiomyopathy during her pregnancy with ejection fraction reaching as low as 20-30%. She delivered via primary low-transverse cesarean section at 37 weeks complicated by uterine atony with an unremarkable recovery. Cardiomyopathy was treated with metoprolol and enalapril and she achieved ejection fraction of 44% at one year follow-up with complete return to baseline activity.

Discussion: We present a woman with a history of doxorubicin therapy who developed peripartum cardiomyopathy and recovered symptomatically after one year. Although treatment of peripartum cardiomyopathy regardless of etiology is well-defined, there are few reports and no standard guidelines for special considerations in pregnant women with a history of doxorubicin therapy, a topic that may warrant further investigation.


Peripartum cardiomyopathy, doxorubicin, osteosarcoma

Total Pages

8 pages

Financial Disclosure

The authors report no conflict of interest


Copyright © 2018 Sraavya S. Akella and Sarah A. Shaffer

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.